Welcome to our dedicated page for Aditxt news (Ticker: ADTX), a resource for investors and traders seeking the latest updates and insights on Aditxt stock.
Aditxt, Inc. reports developments as a life sciences and health-innovation platform with operating subsidiaries focused on diagnostics, precision oncology, and immune-system technologies. Company news includes updates on Ignite Proteomics, a commercial-stage precision oncology business that uses functional protein profiling to support cancer therapy selection, and Pearsanta, which is developing blood-based diagnostic tests including the Mitomic Endometriosis Test.
Recurring ADTX coverage also includes subsidiary leadership, clinical and research publications, acquisition activity, shareholder votes, reverse stock splits, Nasdaq listing matters, and other capital-structure actions tied to the company’s publicly traded common stock.
Aditxt (ADTX) has signed a letter of intent to acquire a biopharmaceutical company focused on COVID-19 antiviral oral therapy, which is commercially available in multiple international markets. The transaction includes a proposed $6.5M secured loan from Aditxt to the target company, with shares issued representing 50% of Aditxt’s outstanding shares post-closing. Completion of the acquisition is contingent on various conditions, including due diligence and shareholder approval, with an exclusivity period ending on September 30, 2021.
Aditxt, Inc. (Nasdaq: ADTX) has partnered with Great Lakes Medical Laboratory (GLML) to provide its AditxtScore™ for COVID-19 across Michigan. This immune response monitoring tool assesses antibody responses to the SARS-CoV-2 virus, offering detailed insights into individual immune strength. Available at GLML's six locations, the AditxtScore aims to clarify immune responses, especially amid vaccine hesitancy. It distinguishes itself by measuring neutralizing antibodies and multiple antigens, facilitating better understanding and management of COVID-19 immunity.
Aditxt, Inc. (Nasdaq: ADTX) has revised the timeline for its Psoriasis clinical program to 2022 due to extended manufacturing processes. The company is enhancing data for regulatory submissions for its Apoptotic DNA Immunotherapy™ (ADi™) platform, which will also study skin allografting and type 1 diabetes. Additionally, Aditxt is expanding its preclinical ADi program to include multiple sclerosis (MS) to address unmet clinical needs. The company has secured 96 patents and 22 pending applications, further protecting its innovations.
Aditxt, Inc. (Nasdaq: ADTX) has enhanced its AditxtScore™ for COVID-19, a multi-dimensional immune response test. This updated version now includes a high-sensitivity neutralizing antibody diagnostic to evaluate individual immune responses to SARS-CoV-2. The test, which captures detailed immune response data, differentiates itself from traditional antibody tests by measuring neutralizing antibodies. This enhancement aims to better identify individuals vulnerable to infection, particularly immunocompromised patients who may have inadequate immune responses due to various health conditions.
Aditxt, Inc. (Nasdaq: ADTX) has launched its AditxtScore™ Center in Richmond, VA, a CLIA-validated facility capable of processing millions of immune system reports annually. This center is pivotal for commercializing the AditxtScore platform, which assesses individual immune biomarkers and aids in health monitoring. The recently commercialized AditxtScore for COVID-19 will detect antibodies against SARS-CoV-2. Aditxt focuses on technologies that enhance immune health, featuring both monitoring and reprogramming solutions.
Aditxt Therapeutics, Inc. (Nasdaq: ADTX) has appointed Dr. Lauren Chung as an independent director to its board. Dr. Chung brings over 20 years of experience in healthcare investment management and advisory roles. In her new role, she will contribute to Aditxt's goals of enhancing the AditxtScore immune intelligence platform and launching clinical studies. Her background includes work at Yozma Group Korea and a history of managing healthcare portfolios. This strategic addition is aimed at bolstering Aditxt's position in the biotech market.
Aditxt Therapeutics (NASDAQ: ADTX) announced its inclusion in the Russell Microcap® Index, effective June 28, 2021. This appointment aims to expand Aditxt's visibility among institutional investors and broaden its shareholder base. Russell indexes, used by many investment managers, represent approximately $10.6 trillion in assets. Aditxt focuses on improving immune system health through innovative technologies, including immune monitoring and reprogramming. The company anticipates that this inclusion will enhance its investment appeal.
Aditx Therapeutics (ADTX) announced a partnership with Meridian Health Services Network to offer AditxtScore for COVID-19, a service that monitors immunity through a comprehensive immune profile. This service allows clients, including major national organizations, to better track their employees' immune responses and increase workplace safety. AditxtScore assesses specific immune biomarkers to provide insights on protection against COVID-19, complementing existing vaccination efforts. The company is seeking 510(K) marketing authorization, and AditxtScore is currently not FDA cleared.
Aditxt (ADTX) has announced plans to establish a new high-capacity AditxtScore™ Center in Richmond, VA, with an investment of $31.5 million over three years. This facility aims to enhance the processing capacity for AditxtScore™, which evaluates immune health by analyzing biomarkers. The center will create over 300 new jobs and is expected to deliver up to 10 million reports annually. This initiative aligns with the company's strategic vision to shift towards proactive immune health monitoring and follows the recent commercialization of the AditxtScore™ for COVID-19.
Aditxt Therapeutics (Nasdaq: ADTX) announced the appointment of Sunny Uberoi as its first Chief Communications Officer. Uberoi will enhance corporate communications and investor relations as the company prepares for its first-in-human clinical trials and the expansion of its AditxtScore platform, aimed at providing comprehensive immune system profiles. His previous experience includes roles at Bristol Myers Squibb, Deloitte, and Pfizer, positioning him to support Aditxt's growth strategy focused on immune health technologies.